Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy - 14/06/24
![](/templates/common/images/mail.png)
Graphical abstract |
Highlights |
• | Mexiletine, an antiarrhythmic agent, can relieve skeletal muscle myotonic symptoms. |
• | In France, mexiletine can be used compassionately for myotonic dystrophy (MD). |
• | An expert group has produced an algorithm for mexiletine use in patients with MD. |
• | Patients with MD need close cardiac monitoring before and during mexiletine use. |
Abstract |
In France, mexiletine – a class I antiarrhythmic drug – can be prescribed for the symptomatic treatment of myotonia of the skeletal muscles in adult patients with myotonic dystrophy under a compassionate use programme. Mexiletine is used according to its summary of product characteristics, which describes its use for myotonia treatment in adult patients with non-dystrophic myotonia, a different neuromuscular condition without cardiac involvement. A cardiac assessment is required prior to initiation and throughout treatment due to potential proarrhythmic effects. The presence of conduction system disease, the most common cardiac manifestation of myotonic dystrophy, mandates repeated cardiac evaluations in patients with this condition, and becomes even more important when they are given mexiletine. A group of experts, including three neurologists and five cardiologists from French neuromuscular reference centres, were involved in a task force to develop a treatment algorithm to guide mexiletine use in myotonic dystrophy. The recommendations are based on data from a literature review of the safety of mexiletine-treated patients with myotonic dystrophy, the compassionate use protocol for mexiletine and the personal clinical experience of the experts. The main conclusion of the expert group is that, although existing safety data in mexiletine-treated patients with myotonic dystrophy are reassuring, cardiac assessments should be reinforced in such patients compared with mexiletine-treated patients with non-dystrophic myotonia. This expert opinion to guide mexiletine treatment in patients with myotonic dystrophy should help to reduce the risk of severe adverse events and facilitate interactions between specialists involved in the routine care of patients with myotonic dystrophy.
Le texte complet de cet article est disponible en PDF.Keywords : Mexiletine, Myotonic dystrophy, Expert opinion, Cardiac safety
Plan
☆ | Tweet: A group of French cardiology and neuromuscular experts has established a new opinion document to improve the safety of mexiletine treatment for myotonia in adult patients with myotonic dystrophy, with a very practical algorithm on pre-treatment assessments and follow-up strategy. |
Vol 117 - N° 6-7
P. 450-456 - juin 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?